Our results revealed that lung cancer patients who received EGFR-TKIs treatment have an odds ratio of VTE incidence of 4.71 (2.90–7.67, P < 0.01) compared with patients without EGFR-TKI treatment. The gene discussed is EGFR; the disease is lung cancer.